Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

NCT03634332 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Pancreatic Neoplasms

Interventions

DRUG: PEGPH20
BIOLOGICAL: Pembrolizumab

Sponsor

Pancreatic Cancer Research Team

Collaborators

[object Object]
[object Object]
[object Object]